positron emission tomography (PET); fluorodeoxyglucose (FDG); radiolabeled antisense oligonucleotide (RASON); human dopamine 2 receptor (hD2R); human somatostatin receptor subtype 2 (hSSTR2); human sodium iodide symporter (hNIS); 9-(4-fluoro-3hydroxymethylbutyl)guanine (FHBG); 2′-fluoro-2′-deoxy-1-β-Darabinofuranosyl-5-iodouracil (FIAU); gastrointestinal stromal tumor (GIST); carcinoembryonic antigen (CEA); HSV1-tk and enhanced GFP fusion gene (TKeGFP); N,N′-bis(2-chloroethyl)-Nnitrosourea (BCNU); prostrate-specific antigen enhancer (PSE); two-step transcriptional amplification (TSTA); dihydrofolate reductase (DHFR); nuclear factor of activated T cells (NFAT).
No takes yet. Share an insight, caveat, or question.
Blasberg et al. (2003) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: